MadeMed Review: Compounded GLP-1 Pricing, FDA Enforcement Context, and What to Verify Before You Enroll

HOUSTON, May 25, 2026 (Newswire.com) - Advertorial Disclosure: This article is sponsored content and contains affiliate links. A commission may be earned if a reader purchases through links in this article, at no additional cost to the reader. This content is for informational purposes only and should not be interpreted as medical advice, a clinical recommendation, or a guarantee of eligibility, pricing, availability, or results. The information in this article reflects MadeMed's published materials, FDA consumer safety communications, and publicly available regulatory information. All prescribing decisions are made solely by licensed clinicians. Not all individuals will qualify for treatment. Pricing, availability, and program terms may change - verify current terms at mademed.com before making any purchasing decision.

MadeMed Review 2026: 5 Things to Verify Before Your First Consultation Call - GLP-1 Pricing, Compounding Disclosures, and the FDA Deadline Every Patient Should Know

Last Verified: Q2 2026 - Pricing, regulatory status, and program terms confirmed against MadeMed's published materials and current FDA communications.

TL;DR - What Every MadeMed Buyer Should Know Before Enrolling

MadeMed is a telehealth platform (IDL Health LLC d/b/a MadeMed) connecting patients with licensed clinicians through Xpedicare, LLC for GLP-1 weight loss, men's wellness, peptide therapy, and NAD+ programs. All treatments require a physician consultation - not every patient qualifies. On April 30, 2026, the FDA proposed excluding semaglutide and tirzepatide from the 503B compounding bulks list (Federal Register docket 2026-08552), with a public comment period closing June 29, 2026. Compounded GLP-1 medications are not FDA-approved finished products. Pricing from $169/month. MadeMed Club: $149/year. LegitScript certified, HIPAA-compliant.

Important Compounded Medication Disclosure: Some medications discussed in this article may be compounded. Compounded drugs are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness, or quality before marketing. MadeMed's own Terms of Use disclose that certain prescription medications available through the platform may be prepared by a compounding pharmacy and that compounded drugs are not approved by the FDA or evaluated for safety or efficacy. Additionally, some medications may be prescribed for uses not yet approved by the FDA for that specific indication - a practice known as off-label prescribing, which is legal and common in clinical practice but which patients should discuss specifically with the prescribing clinician. Patients should discuss all risks, alternatives, dosing, pharmacy sourcing, and eligibility with a licensed healthcare provider before starting any prescription medication.

Review MadeMed's current program options and pricing here

What Changed With Compounded GLP-1 Telehealth in 2026 - And Why It Matters Before You Enroll

If you are researching MadeMed, there is a specific regulatory development that every article published before April 30, 2026 cannot tell you about - because it did not exist until that date. On April 30, 2026, the FDA published a formal proposal in the Federal Register (docket 2026-08552) to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list - the mechanism that has enabled large-scale compounding of these medications. FDA Commissioner Marty Makary stated in the announcement: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need." The public comment period closes June 29, 2026, after which the FDA will issue a final determination. This is not a ban - it is a proposal with a live comment window. But the regulatory direction is unambiguous, and any buyer enrolling in a compounded GLP-1 program while the comment period remains open is doing so before a final regulatory determination has been issued. That April 30 proposal came after the FDA had already documented two prior enforcement waves specifically targeting compounders and telehealth distributors. In September 2025, the FDA issued more than 50 warning letters to companies compounding or marketing semaglutide and tirzepatide - a count reported by Wilson Sonsini Goodrich & Rosati, a national law firm specializing in FDA enforcement, and confirmed by Pharmacy Times. A second wave followed in February 2026: 30 additional warning letters to telehealth companies specifically for false or misleading GLP-1 marketing claims, as reported by Fierce Pharma, Pharmaceutical Commerce, and Drug Topics. Telehealth.org reported the combined 2025 enforcement total exceeded 100 letters to telehealth and compounding providers before the February 2026 wave. The FDA's February 2026 announcement stated that entities marketing unapproved compounded GLP-1 products should be aware that failure to adequately address violations may result in legal action without further notice, including seizure and injunction. The warning letters cited claims that compounded products were equivalent to FDA-approved branded medications, use of trademarked names that obscured the compounded source, and statements that compounded drugs had been tested in the same clinical trials as Wegovy or Zepbound.

This is the regulatory environment any honest GLP-1 telehealth review has to acknowledge. It does not mean that every telehealth platform offering compounded GLP-1 medications is operating unlawfully - Patient-specific compounded medications may be treated differently from mass-marketed copycat products, depending on the prescription, pharmacy, applicable law, and current FDA policy. What it does mean is that the platform's disclosures, prescription model, and pharmacy sourcing are now the most important things to evaluate. Marketing language about "the most effective medication available" - promotional language of this kind - is not the right thing to read. The Terms of Use, the Refund Policy, and the compounding disclosures are.

Federal and state rules may allow certain patient-specific compounded medications under defined conditions, but eligibility, sourcing, and dispensing requirements depend on the facts of the prescription, the pharmacy, and applicable law. That is a conversation to have with a licensed healthcare provider, not something to determine from a product landing page.

For readers who want a comprehensive breakdown of MadeMed's platform structure, how the three-entity model works in practice, and a full verification guide published in April 2026, prior coverage of MadeMed's platform structure and enrollment verification guide covers those details in depth. The sections below focus on what has changed since that analysis and what the current regulatory environment means for buyers enrolling right now.

The 5 Things Every MadeMed Buyer Should Verify Before the Consultation Call

Most people researching GLP-1 telehealth platforms go straight to the pricing page. The five questions below are the ones that actually determine whether a platform is the right fit - and whether you will be surprised after you have already paid. Each is addressed in detail in the sections that follow.

• What is the compounding model? Who prescribes, who fills, and under what legal framework. MadeMed's Terms of Use identify the three-entity structure: IDL Health LLC (platform), Xpedicare, LLC (clinical services), and licensed partner pharmacies (fulfillment). Understand this before the consultation call.

• What does the refund policy actually say? MadeMed's published Refund Policy states all dispensed medication sales are final and non-refundable. The $39 consultation fee is non-refundable after the visit. Critically: completing the intake process and submitting payment does not guarantee that a prescription will be issued - that determination rests entirely with the independent licensed clinician at Xpedicare, LLC. Read the full Refund Policy before submitting any payment.

• What is the billing model - and what is the cancellation effective date? The FAQ and the Terms of Use say slightly different things. The FAQ describes how to pause or cancel. The Terms state cancellations are effective at the end of the current billing period with no prorated refund. Both are true. Both matter.

• Does the program accept insurance, FSA, or HSA? No, no, and no, per MadeMed's published FAQ and Terms. Every dollar is out of pocket. Verify before you are 30 days into a quarterly subscription.

• What is the current FDA regulatory status of the specific medication? Compounded GLP-1 medications are not FDA-approved finished products, and the FDA has proposed excluding semaglutide and tirzepatide from the 503B bulks list (Federal Register docket 2026-08552) - a proposal with a public comment period closing June 29, 2026. Ask the prescribing physician directly about how this affects your specific prescription before any treatment begins.

Review MadeMed's current program options and pricing here

What MadeMed Actually Offers: A Verified Category-by-Category Breakdown

MadeMed's published website covers four treatment categories. All require a physician consultation before any prescription is issued, and the company states clearly that not all consultations result in a prescription. Every item below is sourced directly from MadeMed's published product pages.

GLP-1 Weight Loss: Four Programs, Two Delivery Formats

The weight loss category covers injectable and oral versions of both semaglutide and tirzepatide. MadeMed's product materials describe Injectable Semaglutide as a GLP-1 agonist enhanced with L-Carnitine, with new patients starting at 0.25mg. The published monthly billing price for that starting vial is $179/month. MadeMed's materials include average body weight loss ranges in the product description - these are brand-reported figures, not guarantees, and individual results vary significantly. Treatment requires clinician review, and compounded medications are not FDA-approved finished drug products.

MadeMed's product materials describe Injectable Tirzepatide as a dual GLP-1/GIP agonist also enhanced with L-Carnitine, starting at 2.5mg for $189/month. The dual-receptor mechanism - activating both GLP-1 and GIP receptors rather than GLP-1 alone - is a real pharmacological distinction that MadeMed's FAQ accurately describes. The company's materials note that clinical studies have shown tirzepatide can produce greater average weight loss compared to semaglutide in head-to-head trials, and this reflects published clinical research, though those trials involved FDA-approved branded versions, not compounded formulations. Whether compounded versions produce equivalent results has not been established through the same standard of clinical evidence.

The no-needle options are Oral Semaglutide (sublingual tablet, 30-tablet 1mg supply, $169/month) and Oral Tirzepatide (sublingual tablet, 30-tablet 3mg supply, $229/month). The company states new patients start at 1mg for Oral Semaglutide, and that the prescribing physician determines the starting dose for Oral Tirzepatide. Per the product FAQ, Oral Tirzepatide is currently available in 40 states and is not offered in Alabama, Alaska, Arkansas, Hawaii, Massachusetts, Missouri, New Mexico, New York, South Carolina, or Virginia.

MadeMed's FAQ states that most patients see reduced appetite within one to two weeks and that noticeable weight loss typically occurs within the first four to eight weeks. These are brand-reported timeframes presented as general educational context. A licensed physician's evaluation determines eligibility, and results are not guaranteed.

Men's Wellness: The 3-in-1 Prescription Formula

The men's wellness formula is a compounded sublingual dissolvable tablet combining Tadalafil, PT-141, and Oxytocin. According to MadeMed's published product page, Tadalafil addresses blood flow and circulatory function, PT-141 is a prescription peptide that works through a distinct neurological pathway, and Oxytocin is described as supporting emotional bonding. The company notes that PT-141 carries its own separate FDA approval for a specific prescription indication - a meaningful distinction from the rest of the formula, since the overall compounded combination is not itself FDA-approved as a finished product. Published starting price is $119/month for 8 tablets at 5mg.

A critical drug interaction warning from MadeMed's own published FAQ applies to this formula: Tadalafil must not be taken with nitrates (nitroglycerin, isosorbide) or alpha-blockers due to serious blood pressure interactions. PT-141 should not be used by patients with uncontrolled high blood pressure or cardiovascular disease. These are clinical contraindications that the prescribing physician must review with each patient before any prescription is issued. Eight tablets per month is published as the clinically recommended maximum for the PT-141 component.

Peptide Therapy: Sermorelin, Injectable and Oral

MadeMed offers Injectable Sermorelin at $199/month for a 9mg/3mL vial (30-day supply) and Oral Sermorelin at $149/month for 1000mcg sublingual tablets. The injectable version requires an IGF-1 blood test from Labcorp or Quest before any prescription is issued. The company describes Sermorelin as a growth hormone-releasing peptide supporting sleep, recovery, and energy. These descriptions are drawn from MadeMed's published product materials, not from independent clinical assessment by this publication. A physician consultation and, for the injectable, a lab test are required before prescribing.

NAD+ Therapy: Two Delivery Formats, Lab Test Required

The NAD+ category includes injectable NAD+ at $249/month for 8 injections at 1000mg and NAD+ Nasal Spray at $269/month for a 500mg/15mL 30-day supply. Both require a CMP blood test before prescribing and are described by the company as using patented NanoNAD+ technology. Lab test results from Labcorp or Quest can be uploaded if recently obtained, or a new test can be arranged. These are brand-provided product descriptions; clinical claims about NAD+ therapy should be discussed with a licensed healthcare provider.

See MadeMed's full program lineup and current pricing at the offer page

MadeMed Pricing, Verified: What the Numbers Actually Are and What They Include

All pricing below reflects MadeMed's published product materials at the time of this review and may vary by dose, billing cadence, membership status, availability, and future program changes. Prices adjust upward as a patient's prescribed dose increases during titration. Readers should verify current pricing directly at mademed.com before enrolling.

On a standard monthly billing cycle, per MadeMed's published product pages: Injectable Semaglutide starts at $179/month for a 0.25mg vial. Injectable Tirzepatide starts at $189/month for a 2.5mg vial. Oral Semaglutide starts at $169/month for a 30-tablet 1mg supply. Oral Tirzepatide starts at $229/month for a 30-tablet 3mg supply. The 3-in-1 men's wellness formula starts at $119/month for 8 tablets at 5mg. Injectable Sermorelin is $199/month, Oral Sermorelin $149/month, NAD+ Injectable $249/month, and NAD+ Nasal Spray $269/month.

Each program includes board-certified physician consultation and free discreet shipping, per the company's published materials. Injectable programs include injection supplies. The same product pages show lower "from" pricing language in certain card descriptions - this likely reflects quarterly billing or membership pricing. MadeMed Club membership ($149/year) provides the rates described in the membership section below. Dose pricing increases are disclosed to the patient before each shipment, per the company's published FAQ.

MadeMed Club Membership: What the Math Says

MadeMed Club is an optional annual membership at $149/year. Per the company's published pricing, Club members receive monthly savings that vary by product: $10/month on Injectable Semaglutide, $20/month on Injectable Tirzepatide, $10/month on Oral Semaglutide, $20/month on Oral Tirzepatide, $10/month on the men's wellness formula, $10/month on Oral Sermorelin, and $20/month on both NAD+ products.

Based on MadeMed's published $149/year membership fee and listed monthly savings, a patient saving $20/month would offset the annual membership cost after approximately 7.5 months. A patient saving $10/month would offset it after approximately 14.9 months. This is arithmetic based on published figures - not a recommendation to enroll. Whether membership makes financial sense depends on product selection, expected treatment duration, current pricing terms, and individual eligibility, all of which a patient should evaluate before enrolling. The company compares its Club model to a Costco membership. That is a marketing framing, not a clinical or regulatory claim.

What MadeMed's Own Published Terms Reveal That the Product Pages Don't Lead With

These are not buried in the fine print - they are published openly by MadeMed. But they are exactly the kind of details that get skipped when someone is excited about finally finding an affordable GLP-1 option. Read them before you enroll.

All sales are final once medication is dispensed. MadeMed's published Refund Policy states that federal and state laws prohibit accepting returns on medication once it has been dispensed by the pharmacy, and that all sales of prescription and over-the-counter products are final and non-refundable. If a consultation ends without a prescription being written, the company states a full refund minus a $39 doctor visit fee is issued. Read the full Refund Policy at mademed.com/returns before submitting any payment.

No insurance. No FSA. No HSA. MadeMed's published FAQ and Terms of Use both state that the platform does not accept insurance, and that FSA and HSA cards are not currently accepted for payment. MadeMed and Xpedicare, LLC are not insurers. All costs are on a cash basis. If your household budget depends on insurance offset or tax-advantaged accounts, that is a material factor in this decision - not a detail to sort out after enrolling.

Compounded medications are not FDA-approved finished products. MadeMed's Terms of Use state this directly, and it is worth reading in the company's own words, not paraphrased. The broader FDA enforcement environment around compounded GLP-1 marketing is active and ongoing. Buyers should discuss the current regulatory landscape and personal risk factors with a licensed healthcare provider through the consultation process - before any prescription is written, not after.

Who Actually Operates MadeMed, Who Prescribes, and Who Fills - The Three-Entity Structure Explained

Understanding who does what at MadeMed matters more in this category than in most. The company's Terms of Use draw a clear line between three entities.

MadeMed itself is operated by IDL Health LLC (d/b/a MadeMed), headquartered at 9668 Westheimer Rd Suite 200 #32, Houston, TX 77063. Per the Terms of Use, MadeMed provides non-clinical site services - it operates the platform but does not provide medical advice or care directly.

Xpedicare, LLC is described in the Terms as an independent professional entity solely responsible for providing clinical services and making all medical decisions. Providers are independently contracted or employed by Xpedicare, LLC, not by MadeMed. The doctor-patient relationship is with Xpedicare's providers, not with MadeMed. Any information or advice received from a provider comes from the provider, not from MadeMed.

Prescription fulfillment is handled through licensed partner pharmacies. The Terms of Use identify AbsoluteRx as a partner pharmacy, and Red Rock Pharmacy is identified on the company's About page. All medications are described as prepared in licensed, accredited US compounding pharmacies under the supervision of licensed pharmacists.

The Medical Director is identified on the About page as Dr. Thai Pham, a Brown University-educated internist with over 25 years of clinical experience. The platform holds LegitScript certification and is described as HIPAA-compliant. Xpedicare, LLC is identified as a Covered Entity under HIPAA in the Terms of Use. Customer support: support@mademed.com and +1 (800) 582-1428.

Billing and Subscriptions: Read the FAQ and the Terms of Use - They Are Not the Same Document

Both the FAQ and the Terms of Use address subscription billing, and they say slightly different things. Reading only the FAQ is not enough.

The FAQ states that MadeMed emails customers 7 days before every charge with the exact amount and options to pause, skip, or cancel. Dashboard cancellation is described as one click. Billing pauses are described as immediate - not "next cycle," the FAQ states, immediately.

The Terms of Use state that cancellations are effective at the end of the current billing period and that prorated refunds are not offered. Both statements are accurate and not in conflict, but they describe different scenarios: the FAQ describes how to initiate a pause or cancel, and the Terms describe the effective date and refund treatment after cancellation is processed.

The practical meaning: pausing stops future charges. Canceling ends the subscription at the end of the period already paid. Neither results in a partial refund of a period already in progress. That is worth understanding before choosing a billing cadence, especially for quarterly plans where more money is committed in a single charge.

View current MadeMed program availability and start the consultation process here

Frequently Asked Questions About MadeMed

Is MadeMed legit?

MadeMed presents itself as a telehealth platform operated by IDL Health LLC (d/b/a MadeMed), with clinical services provided by Xpedicare, LLC and its affiliated physicians and providers. MadeMed's published materials state that the platform is HIPAA-compliant and LegitScript certified - LegitScript is a third-party standards body for online pharmacy and telehealth operations. These disclosures support the conclusion that MadeMed operates a structured telehealth pathway with defined physician oversight and pharmacy partners. Readers should still verify current certification status, state availability, prescription requirements, pharmacy sourcing, and medical eligibility at mademed.com before enrolling, because a structured platform is not the same as a guarantee of eligibility, outcome, or that any specific medication is right for any specific patient. For a detailed breakdown of MadeMed's published terms and platform verification steps, an earlier breakdown of MadeMed's three-entity structure and enrollment guide provides additional context.

What GLP-1 medications does MadeMed offer?

According to MadeMed's published product pages, the platform offers compounded Injectable Semaglutide ($179/month starting), Injectable Tirzepatide ($189/month starting), Oral Semaglutide ($169/month starting), and Oral Tirzepatide ($229/month starting). All require physician consultation and are not available to every patient. All are compounded medications - not FDA-approved finished drug products. The FDA has not reviewed these products for safety, effectiveness, or quality before marketing. Buyers should discuss eligibility, sourcing, and risk with a licensed healthcare provider before starting any GLP-1 program.

Does MadeMed accept insurance, FSA, or HSA?

No. Per MadeMed's published FAQ and Terms of Use, the platform does not accept insurance. FSA and HSA cards are also not currently accepted for payment. All costs are paid on a cash basis. The company's model is direct-to-patient pricing designed to remove insurance intermediary markups - but each buyer should evaluate the full out-of-pocket cost against their own financial situation before committing.

What is the MadeMed Club and is the math right?

MadeMed Club is an optional annual membership at $149/year. Per published pricing, members receive $10-$20/month in savings depending on the product. At $20/month savings - applicable to Injectable Tirzepatide, Oral Tirzepatide, and both NAD+ products - the $149/year fee recoups in approximately 7.5 months. At $10/month savings, it recoups in approximately 14.9 months. Whether the membership makes financial sense depends on product selection, expected treatment duration, and current pricing terms - not on the math alone. All figures should be verified at mademed.com before enrolling.

What is MadeMed's refund policy?

MadeMed's published Refund Policy states that all prescription and non-prescription product sales are final and non-refundable once medication has been dispensed by the pharmacy. Medical consultation fees are non-refundable after the consultation has been completed. Exceptions apply only for damaged, incorrect, or lost orders - buyers must contact support@mademed.com within seven days of delivery with the order number and, where applicable, photographic evidence of the issue.

What states does MadeMed serve?

MadeMed's published FAQ lists 40 states where the platform currently operates. Oral Tirzepatide is specifically unavailable in Alabama, Alaska, Arkansas, Hawaii, Massachusetts, Missouri, New Mexico, New York, South Carolina, and Virginia. State availability for all other programs should be verified directly at mademed.com before enrolling, since availability is subject to state law and may change without notice.

Is compounded semaglutide or tirzepatide FDA-approved?

No. Compounded semaglutide, tirzepatide, and related GLP-1 medications are not FDA-approved finished drug products. They are not reviewed by the FDA for safety, effectiveness, or quality before marketing. The FDA documented two enforcement waves: more than 50 warning letters in September 2025 to companies compounding or marketing semaglutide and tirzepatide (reported by Wilson Sonsini Goodrich & Rosati and Pharmacy Times), followed by 30 additional warning letters in February 2026 to telehealth companies for false or misleading GLP-1 marketing claims (reported by Fierce Pharma and Pharmaceutical Commerce). The FDA's stated position is that compounded drugs are distinct from FDA-approved medications and that mass-marketed compounding of these agents operates outside the intended scope of the compounding exemptions. The fact that a platform requires physician consultation, holds LegitScript certification, and uses licensed US pharmacies does not change the compounded regulatory status of the medications themselves. Buyers should discuss all of this with a licensed healthcare provider before starting any compounded GLP-1 program.

What is in MadeMed's 3-in-1 men's wellness formula?

According to MadeMed's product page, each tablet contains Tadalafil (20mg, addressing blood flow and circulatory function), PT-141 (a prescription peptide with its own separate FDA approval for a specific clinical indication), and Oxytocin (described as supporting emotional bonding). The PT-141 component's separate FDA approval is a meaningful distinction, though the overall compounded combination is not itself an FDA-approved finished product. Starting price is $119/month for 8 tablets at 5mg. The clinically recommended maximum is 8 tablets per month per the PT-141 dosing guidelines. Critical drug interaction: Tadalafil must not be taken with nitrates or alpha-blockers. PT-141 must not be used by patients with uncontrolled hypertension or cardiovascular disease. These contraindications must be reviewed with the prescribing physician.

Does MadeMed require a prescription for all products?

Yes. MadeMed's published FAQ states that all treatments require a prescription and that the online physician consultation determines whether a patient is a candidate. Not all consultations result in a prescription. Patients who do not receive a prescription are refunded in full minus the $39 consultation fee.

What are the common side effects of GLP-1 medications?

MadeMed's published FAQ states: "The most common side effects are nausea, diarrhea, and decreased appetite (which is therapeutic). These are typically mild and subside within 1-2 weeks as your body adjusts. Serious side effects are rare but include pancreatitis and gallbladder issues." These descriptions are consistent with publicly available clinical literature on GLP-1 medications. Individual experiences vary considerably. A complete medication history and health disclosure during the physician consultation is essential, particularly for patients with gastrointestinal conditions or a history of pancreatitis.

What happens if you stop taking GLP-1 medication?

MadeMed's FAQ addresses this directly: weight regain is common after stopping, appetite returns to baseline, and some or all weight lost may return. Some patients transition to lifestyle changes developed during treatment; others stay on a maintenance dose long-term to prevent regain. These descriptions are consistent with what the clinical literature reports about GLP-1 medication discontinuation. Stopping treatment should be planned with the prescribing physician - not done unilaterally.

What lab tests does MadeMed require?

Per MadeMed's published product pages: Injectable Sermorelin requires an IGF-1 blood test at Labcorp or Quest before prescribing. Both NAD+ products require a CMP blood test. GLP-1 and tadalafil product pages do not specify advance lab requirements, though the physician consultation will assess eligibility based on individual health history. Lab requirements should be confirmed with MadeMed before enrolling in any program, as clinical requirements may change.

How does MadeMed's consultation process work?

Per the published How It Works page: complete a secure online health questionnaire (approximately 5 minutes); a licensed physician reviews the submission and, if appropriate, issues a prescription within 24 hours; medication ships from a licensed US pharmacy with free discreet shipping. No video call is required. The physician-patient relationship is with the licensed clinician at Xpedicare, LLC, not with MadeMed. Secure messaging with the medical team is available throughout the treatment period.

Check current MadeMed program details and begin the intake process at the offer page

Bottom Line on MadeMed: What to Do Next and What to Ask First

Here is the honest answer a well-informed buyer needs.

MadeMed offers a structured, physician-first telehealth model with transparent published pricing, named medical leadership, LegitScript certification, and explicit compounding disclosures in its own Terms of Use. Those are meaningful signals that the platform takes its compliance obligations seriously. The Medical Director is named and credentialed. The platform structure - MadeMed as the non-clinical operator, Xpedicare as the independent medical group, licensed US partner pharmacies for fulfillment - is disclosed clearly in the Terms, not buried.

At the same time, anyone evaluating this platform should understand three facts with real clarity: compounded GLP-1 medications are not FDA-approved; the FDA has documented two enforcement waves against GLP-1 compounders and telehealth marketers since September 2025 - more than 50 warning letters in that month and 30 more in February 2026, per reporting from legal and healthcare trade publications; and all sales are final once medication is dispensed. None of these facts necessarily mean MadeMed is the wrong choice for a given patient - but they are facts that belong in the decision, not in the footnotes.

The smartest thing a prospective MadeMed patient can do is exactly what MadeMed's own intake process requires: talk to a licensed physician, disclose your full health history and current medications, ask specifically about the compounding pharmacy, ask about drug interactions, and make the decision with a clinician rather than from a product page. That is what the platform is designed for. Use it.

Contact MadeMed at support@mademed.com or +1 (800) 582-1428 for questions about program availability, state eligibility, or consultation scheduling.

FDA Disclaimer: The statements in this article have not been evaluated by the Food and Drug Administration. Products discussed are not intended to diagnose, treat, cure, or prevent any disease. Compounded medications discussed herein are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness, or quality before marketing. This content is for general informational purposes only and does not constitute medical advice. Readers considering changes to health regimens should consult a licensed healthcare professional. Individual results vary.

FTC Affiliate Disclosure: This article is sponsored content and contains affiliate links. A commission may be earned on qualifying purchases made through links in this content, at no additional cost to the reader. Disclosure is provided in accordance with FTC 16 CFR Part 255.

Results Disclaimer: Individual results vary. Weight loss outcomes, treatment responses, and all results described in this article reflect brand-reported data from MadeMed's published materials. No specific outcome is guaranteed. Results depend on individual health status, physician determination of eligibility, adherence to prescribed protocols, and other factors outside the platform's control.

Medical Advice Disclaimer: Nothing in this article constitutes medical advice, diagnosis, or treatment. All prescribing decisions are made solely by licensed clinicians employed by or contracted with Xpedicare, LLC. MadeMed does not provide medical care directly. Consult a qualified healthcare professional before making any decision about prescription medications or telehealth services.

Pricing Disclaimer: All pricing referenced reflects MadeMed's published product pages at the time of this review. Prices are subject to change without notice and may vary by dose, billing cadence, and membership status. Verify current pricing and program terms directly at mademed.com before making any purchasing decision.

Compounding Disclosure: Compounded medications discussed in this article are not FDA-approved finished drug products and have not been evaluated by the FDA for safety or efficacy. The compounding pharmacy regulatory environment is subject to ongoing change based on applicable federal and state law and FDA enforcement activity. Buyers should consult a licensed healthcare provider regarding the current status of any compounded medication program before enrolling.

Publisher Independence Disclaimer: This content was prepared independently and does not represent the editorial positions of Accesswire, Newswire.com, or any distribution partner. The publisher is not responsible for changes to brand offerings, pricing, or product availability after publication.

Platform Disclosure: MadeMed is a telehealth platform operated by IDL Health LLC (d/b/a MadeMed), 9668 Westheimer Rd Suite 200 #32, Houston, TX 77063. Professional medical services are provided by Xpedicare, LLC, an independent medical group. MadeMed and Xpedicare, LLC are not insurers. This is not an insurance product. Not available in all states.

SOURCE: MadeMed

Source: MadeMed